Muromonab-CD3 - Wikipedia
网页Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants. [1] [2] It is a monoclonal antibody targeted at the CD3 receptor, [3] a membrane protein on the surface of T cells.
Muromonab: Uses, Interactions, Mechanism of Action - DrugBank …
网页Muromonab is a monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Muromonab CD3. A review of its pharmacology and therapeutic …
网页Muromonab CD3 (Orthoclone OKT3, Orthoclone, OKT3) is the first monoclonal antibody to become available for therapy in humans. In effect it blocks all cytotoxic T cell function. Clinical trials show that muromonab CD3 is effective in reversing acute renal, hepatic, cardiac and combined kidney-pancrea ….
Muromonab-Cd3 (Intravenous Route) Description and Brand Names - Mayo Clinic
网页2024年2月1日 · Muromonab-CD3 is a monoclonal antibody. It is used to reduce the body's natural immunity in patients who receive organ (for example, kidney) transplants. When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ.
The first monoclonal antibody therapy - Nature
网页2018年12月10日 · The work of Yednock and colleagues had been preceded in 1986 by FDA approval of the first ever monoclonal antibody treatment, muromonab-CD3 (anti-CD3), a mouse antibody for the prevention of...
Nature系列综述：抗体药物发展概况 - 健康界
网页2021年8月8日 · 1986 年，OKT3 改名为 muromonab-CD3，获得了 FDA 的第一个治疗性单克隆抗体批准。 但是此技术生产的是鼠源性的单克隆抗体，用于人身上会有强烈的免疫反应，因此单克隆抗体经历了一段鼠源 - 鼠源人源嵌合体 - 全人源化改造的历程。
Muromonab-CD3 - LiverTox - NCBI Bookshelf
网页2020年12月28日 · Muromonab-CD3 is a mouse monoclonal antibody to CD3, often referred to as OKT3, which was withdrawn from use in 2010 but was previously used to treat acute cellular rejection after solid organ transplantation. Muromonab has been linked to mild and transient serum enzyme elevations during therapy, but …
The mouse that roared for human advantage - Nature
网页The first therapeutic antibody was approved by the FDA in 1986 — the mouse mAb muromonab-CD3, to prevent kidney transplant rejection. However, the last couple of decades have seen a dramatic...
Muromonab CD-3: a review of its pharmacology, …
网页Muromonab CD-3 (OKT-3) is a monoclonal antibody that is highly effective in the treatment of acute rejection in solid organ transplants. Due to its monoclonal nature, each molecule is identical because it is derived from a single antibody-producing clone. OKT-3 is administered only by intravenous in ….
FDA approves 100th monoclonal antibody product - Nature
网页2021年5月5日 · In 1986, OKT3 — then renamed muromonab-CD3 — secured a first therapeutic monoclonal antibody approval from the FDA. “It was an explosive time,” says Schlossman. “Everything we touched was gold.”...
- 某些结果已被删除
跳至内容